Bank of America
AMAM

Bank of America’s Ambrx Biopharma Inc AMAM Stock Holding History

Bank of America’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,733
Closed -$523K – 8350
2023
Q4 		$523K Buy
36,733
+36,233
+7,247% +$412K ﹤0.01% 5462
2023
Q3 		$5.75K Sell
500
-58
-10% -$790 ﹤0.01% 6965
2023
Q2 		$9.19K Buy
558
+454
+437% +$5.71K ﹤0.01% 6886
2023
Q1 		$928 Buy
104
+4
+4% +$20 ﹤0.01% 7316
2022
Q4 		$227 Sell
100
-1
-1% -$1 ﹤0.01% 7531
2022
Q3 		$0 Hold
101
– – ﹤0.01% 8333
2022
Q2 		$0 Sell
101
-140
-58% -$534 ﹤0.01% 8553
2022
Q1 		$1K Buy
241
+110
+84% +$563 ﹤0.01% 8160
2021
Q4 		$1K Buy
131
+30
+30% +$335 ﹤0.01% 8112
2021
Q3 		$1K Sell
101
-9
-8% -$162 ﹤0.01% 8036
2021
Q2 		$2K Buy
+110
New +$1.88K ﹤0.01% 7566

Bank of America's AMAM Position: Q1 2024 in Review

Bank of America sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 36,733 shares — an estimated $523K sold.

Bank of America first reported a position in AMAM in Q2 2021 and held it in 11 quarters. The position peaked at $523K in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

  • Bank of America reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
  • Bank of America sold 36,733 Ambrx Biopharma Inc shares in Q1 2024, an estimated $523K.
  • Bank of America first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 11 quarters.
  • Bank of America's Ambrx Biopharma Inc position peaked at $523K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.